サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439638

次世代シーケンシング（NGS）- 世界市場の考察、競合情勢、市場予測（2030年）

Next Generation Sequencing - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.41円
次世代シーケンシング（NGS）- 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の次世代シーケンシング（NGS）の市場規模は、2023年に92億8,000万米ドル、2030年までに263億米ドルに達し、2024年～2030年の予測期間にCAGRで18.96％の成長が見込まれます。次世代シーケンシング（NGS）に対する需要の増加は主に、COVID-19の突然の発生などの感染症の症例の増加や、世界のがんの負担の増大に起因しています。さらに、臨床診断や科学研究におけるNGS技術の応用の増加、NGS技術が示す効率的なターンアラウンド結果、高速性、正確性などの利点は、今後数年間の世界の次世代シーケンシング（NGS）市場の成長に寄与する要因です。

次世代シーケンシング（NGS）の市場力学

次世代シーケンシング（NGS）市場は、世界中でCOVID-19感染者が急増しているため、現在急成長しています。これは、COVIDウイルスが発生時から進化しており、PCR検査ではウイルスの存在しか判定できないためです。一方、NGS技術はCOVID-19ウイルスの新型株の判定や監視に使用されます。

世界保健機関（WHO）の2022年12月22日のデータによると、COVID-19の確定症例は世界中で約2億7,523万3,892件報告されています。

さらに、世界のがん患者の負担の増大も次世代シーケンシング（NGS）市場に寄与すると予測されています。これは、がんバイオマーカーの検出におけるNGS技術ベースのプラットフォームの重要性が高まっているためです。GLOBOCAN directoryが2020年に発表したデータによると、同年には世界で約1,929万2,789件の新たながん症例が検出されました。

さらに、感染症や遺伝性疾患などのさまざまな疾患の検出に向けたNGS技術ベースの製品の承認が、予測期間に次世代シーケンシング（NGS）市場に寄与すると見込まれます。例えば、2020年09月08日、米国FDAはBlueprint Medicinesが開発した標的治療薬GAVRETO（TM）（pralsetinib）の候補となるRET融合遺伝子陽性の転移性非小細胞肺がん（NSCLC）患者を同定するコンパニオン診断薬（CDx）として、Thermo Fisher Scientificが開発したOncomine Dx Target検査に市販前承認を与えました。GAVRETO（TM）は、FDAが承認した3つのNSCLC治療薬に関連するバイオマーカーを対象とした、初の次世代シーケンシング（NGS）ベースのCDxです。

しかし、NGS技術における短いリード長や器具とサービスの高いコストといった特定の要因が、次世代シーケンシング（NGS）市場の成長を阻害する可能性が高いです。

前例のないCOVID-19パンデミックは、次世代シーケンシング（NGS）市場にプラスの効果をもたらしています。NGS技術は、COVID-19の診断に向けた費用対効果の高い分子検査であり、シングルステップのRNA抽出を使用し、ゴールドスタンダードであるRT-qPCRと比較して高いスケーラビリティと精度を示すからです。さらに、SARS-CoV-2に対する次世代シーケンシング（NGS）検査の緊急使用認可（EUA）が増加したことも、パンデミック危機における市場成長につながっています。例えば、2020年6月10日、Illumina, Inc.は米国FDAからSARS-CoV-2の検出を可能にするハイスループット、次世代シーケンシング（NGS）ベースの体外診断（IVD）ワークフローであるIllumina COVID-19Seq（TM）Testの緊急使用認可（EUA）を取得しました。さらに、次世代シーケンシング（NGS）技術を臨床診断検査として取り入れたことや、特にCOVID-19パンデミックがさまざまな検査機関で発生したことも、パンデミック中の市場を強化しました。例えば、2020年8月、Helix Laboratoryは、COVID-19が疑われる人の上気道検体中のSARS-CoV-2由来の核酸の定性的な検出に向けて開発されたアンプリコンベースの次世代シーケンシング（NGS）検査であるCOVID-19 NGS検査のFDA承認を取得しました。

当レポートでは、世界の次世代シーケンシング（NGS）市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 次世代シーケンシング（NGS）市場レポートのイントロダクション

第2章 次世代シーケンシング（NGS）市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 次世代シーケンシング（NGS）市場の主な要因の分析

  • 次世代シーケンシング（NGS）市場の促進要因
    • 世界中でのがんの負担の増大
    • 世界中でのCOVID-19などの感染症の罹患率の増加
    • 次世代シーケンシング（NGS）製品の迅速な承認
    • 次世代シーケンシング（NGS）製品の製造における技術の進歩
  • 次世代シーケンシング（NGS）市場の抑制要因と課題
    • 次世代シーケンシング（NGS）の器具とサービスに関連する高いコスト
    • 大半のNGSベースのプラットフォームにおける短いリード長
  • 次世代シーケンシング（NGS）市場の機会
    • 低中所得国が次世代シーケンシング（NGS）市場にとっての大きな機会を持つ
    • 世界と地域のメーカーによる戦略的事業活動が次世代シーケンシング（NGS）市場に機会をもたらす

第5章 次世代シーケンシング（NGS）のポーターのファイブフォース分析

第6章 次世代シーケンシング（NGS）市場に対するCOVID-19の影響分析

第7章 次世代シーケンシング（NGS）市場のレイアウト

  • 製品タイプ別
    • 器具
    • 試薬・消耗品
    • サービス
  • シーケンシングタイプ別
    • 全ゲノム配列決定
    • 全エクソームシーケンシング
    • RNAシーケンシング
    • ターゲットシーケンシング
    • デノボシーケンシング
    • その他
  • 用途別
    • 診断
    • 創薬
    • 農業・動物研究
  • エンドユーザー別
    • 製薬・バイオテクノロジー企業
    • 病院・診療所
    • 学術・研究機関
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 次世代シーケンシング（NGS）：世界の企業シェア分析 - 主要3～5社

第9章 次世代シーケンシング（NGS）の企業と製品のプロファイル

  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Illumina Inc
  • Bio-Rad Laboratories, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • PerkinElmer Inc.
  • MedGenome
  • BGI
  • Pacific Biosciences
  • GENEWIZ
  • Oxford Nanopore Technologies plc.
  • Psomagen, Inc.
  • 10x Genomics
  • Takara Bio Inc.
  • Zymo Research Corporation.
  • NuGEN Technologies, Inc. (Tecan Trading AG)
  • Vela Diagnostics
  • CD Genomics.
  • HTG Molecular Diagnostics, Inc.

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Next-Generation Sequencing Market
  • Table 3 Next-Generation Sequencing Market Analysis in Global (2021-2030)
  • Table 4 Next-Generation Sequencing Market Analysis in Global by Product Type (2021-2030)
  • Table 5 Next-Generation Sequencing Market Analysis in Global by Sequencing Type (2021-2030)
  • Table 6 Next-Generation Sequencing Market Analysis in Global by Application (2021-2030)
  • Table 7 Next-Generation Sequencing Market Analysis in Global by End User (2021-2030)
  • Table 8 Next-Generation Sequencing Market Analysis in Global by Geography (2021-2030)
  • Table 9 Next-Generation Sequencing Market Analysis in North America (2021-2030)
  • Table 10 Next-Generation Sequencing Market Analysis in North America by Product Type (2021-2030)
  • Table 11 Next-Generation Sequencing Market Analysis in North America by Sequencing Type (2021-2030)
  • Table 12 Next-Generation Sequencing Market Analysis in North America by Application (2021-2030)
  • Table 13 Next-Generation Sequencing Market Analysis in North America by End User (2021-2030)
  • Table 14 Next-Generation Sequencing Market Analysis in North America by Country (2021-2030)
  • Table 15 Next-Generation Sequencing Market Analysis in the US (2021-2030)
  • Table 16 Next-Generation Sequencing Market Analysis in Canada (2021-2030)
  • Table 17 Next-Generation Sequencing Market Analysis in Mexico (2021-2030)
  • Table 18 Next-Generation Sequencing Market Analysis in Europe (2021-2030)
  • Table 19 Next-Generation Sequencing Market Analysis in Europe by Product Type (2021-2030)
  • Table 20 Next-Generation Sequencing Market Analysis in Europe by Sequencing Type (2021-2030)
  • Table 21 Next-Generation Sequencing Market Analysis in Europe by Application (2021-2030)
  • Table 22 Next-Generation Sequencing Market Analysis in Europe by End User (2021-2030)
  • Table 23 Next-Generation Sequencing Market Analysis in Europe by Country (2021-2030)
  • Table 24 Next-Generation Sequencing Market Analysis in France (2021-2030)
  • Table 25 Next-Generation Sequencing Market Analysis in Germany (2021-2030)
  • Table 26 Next-Generation Sequencing Market Analysis in the UK (2021-2030)
  • Table 27 Next-Generation Sequencing Market Analysis in Italy (2021-2030)
  • Table 28 Next-Generation Sequencing Market Analysis in Spain (2021-2030)
  • Table 29 Next-Generation Sequencing Market Analysis in Russia (2021-2030)
  • Table 30 Next-Generation Sequencing Market Analysis in Rest of Europe (2021-2030)
  • Table 31 Next-Generation Sequencing Market Analysis in Asia-Pacific (2021-2030)
  • Table 32 Next-Generation Sequencing Market Analysis in Asia-Pacific by Product Type (2021-2030)
  • Table 33 Next-Generation Sequencing Market Analysis in Asia-Pacific by Sequencing Type (2021-2030)
  • Table 34 Next-Generation Sequencing Market Analysis in Asia-Pacific by Application (2021-2030)
  • Table 35 Next-Generation Sequencing Market Analysis in Asia-Pacific by End User (2021-2030)
  • Table 36 Next-Generation Sequencing Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 37 Next-Generation Sequencing Market Analysis in China (2021-2030)
  • Table 38 Next-Generation Sequencing Market Analysis in Japan (2021-2030)
  • Table 39 Next-Generation Sequencing Market Analysis in India (2021-2030)
  • Table 40 Next-Generation Sequencing Market Analysis in Australia (2021-2030)
  • Table 41 Next-Generation Sequencing Market Analysis in South Korea (2021-2030)
  • Table 42 Next-Generation Sequencing Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Table 43 Next-Generation Sequencing Market Analysis in Rest of World (2021-2030)
  • Table 44 Next-Generation Sequencing Market Analysis in Rest of World by Product Type (2021-2030)
  • Table 45 Next-Generation Sequencing Market Analysis in Rest of World by Sequencing Type (2021-2030)
  • Table 46 Next-Generation Sequencing Market Analysis in Rest of World by Application (2021-2030)
  • Table 47 Next-Generation Sequencing Market Analysis in Rest of World by End User (2021-2030)
  • Table 48 Next-Generation Sequencing Market Analysis in Rest of World by Country (2021-2030)
  • Table 49 Next-Generation Sequencing Market Analysis in the Middle East (2021-2030)
  • Table 50 Next-Generation Sequencing Market Analysis in Africa (2021-2030)
  • Table 51 Next-Generation Sequencing Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Next-Generation Sequencing Market
  • Figure 3 Next-Generation Sequencing Market Analysis in Global (2021-2030)
  • Figure 4 Next-Generation Sequencing Market Analysis in Global by Product Type (2021-2030)
  • Figure 5 Next-Generation Sequencing Market Analysis in Global by Sequencing Type (2021-2030)
  • Figure 6 Next-Generation Sequencing Market Analysis in Global by Application (2021-2030)
  • Figure 7 Next-Generation Sequencing Market Analysis in Global by End User (2021-2030)
  • Figure 8 Next-Generation Sequencing Market Analysis in Global by Geography (2021-2030)
  • Figure 9 Next-Generation Sequencing Market Analysis in North America (2021-2030)
  • Figure 10 Next-Generation Sequencing Market Analysis in North America by Product Type (2021-2030)
  • Figure 11 Next-Generation Sequencing Market Analysis in North America by Sequencing Type (2021-2030)
  • Figure 12 Next-Generation Sequencing Market Analysis in North America by Application (2021-2030)
  • Figure 13 Next-Generation Sequencing Market Analysis in North America by End User (2021-2030)
  • Figure 14 Next-Generation Sequencing Market Analysis in North America by Country (2021-2030)
  • Figure 15 Next-Generation Sequencing Market Analysis in the US (2021-2030)
  • Figure 16 Next-Generation Sequencing Market Analysis in Canada (2021-2030)
  • Figure 17 Next-Generation Sequencing Market Analysis in Mexico (2021-2030)
  • Figure 18 Next-Generation Sequencing Market Analysis in Europe (2021-2030)
  • Figure 19 Next-Generation Sequencing Market Analysis in Europe by Product Type (2021-2030)
  • Figure 20 Next-Generation Sequencing Market Analysis in Europe by Sequencing Type (2021-2030)
  • Figure 21 Next-Generation Sequencing Market Analysis in Europe by Application (2021-2030)
  • Figure 22 Next-Generation Sequencing Market Analysis in Europe by End User (2021-2030)
  • Figure 23 Next-Generation Sequencing Market Analysis in Europe by Country (2021-2030)
  • Figure 24 Next-Generation Sequencing Market Analysis in France (2021-2030)
  • Figure 25 Next-Generation Sequencing Market Analysis in Germany (2021-2030)
  • Figure 26 Next-Generation Sequencing Market Analysis in the UK (2021-2030)
  • Figure 27 Next-Generation Sequencing Market Analysis in Italy (2021-2030)
  • Figure 28 Next-Generation Sequencing Market Analysis in Spain (2021-2030)
  • Figure 29 Next-Generation Sequencing Market Analysis in Russia (2021-2030)
  • Figure 30 Next-Generation Sequencing Market Analysis in Rest of Europe (2021-2030)
  • Figure 31 Next-Generation Sequencing Market Analysis in Asia-Pacific (2021-2030)
  • Figure 32 Next-Generation Sequencing Market Analysis in Asia-Pacific by Product Type (2021-2030)
  • Figure 33 Next-Generation Sequencing Market Analysis in Asia-Pacific by Sequencing Type (2021-2030)
  • Figure 34 Next-Generation Sequencing Market Analysis in Asia-Pacific by Application (2021-2030)
  • Figure 35 Next-Generation Sequencing Market Analysis in Asia-Pacific by End User (2021-2030)
  • Figure 36 Next-Generation Sequencing Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 37 Next-Generation Sequencing Market Analysis in China (2021-2030)
  • Figure 38 Next-Generation Sequencing Market Analysis in Japan (2021-2030)
  • Figure 39 Next-Generation Sequencing Market Analysis in India (2021-2030)
  • Figure 40 Next-Generation Sequencing Market Analysis in Australia (2021-2030)
  • Figure 41 Next-Generation Sequencing Market Analysis in South Korea (2021-2030)
  • Figure 42 Next-Generation Sequencing Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Figure 43 Next-Generation Sequencing Market Analysis in Rest of World (2021-2030)
  • Figure 44 Next-Generation Sequencing Market Analysis in Rest of World by Product Type (2021-2030)
  • Figure 45 Next-Generation Sequencing Market Analysis in Rest of World by Sequencing Type (2021-2030)
  • Figure 46 Next-Generation Sequencing Market Analysis in Rest of World by Application (2021-2030)
  • Figure 47 Next-Generation Sequencing Market Analysis in Rest of World by End User (2021-2030)
  • Figure 48 Next-Generation Sequencing Market Analysis in Rest of World by Country (2021-2030)
  • Figure 49 Next-Generation Sequencing Market Analysis in the Middle East (2021-2030)
  • Figure 50 Next-Generation Sequencing Market Analysis in Africa (2021-2030)
  • Figure 51 Next-Generation Sequencing Market Analysis in South America (2021-2030)
  • Figure 52 Market Drivers
  • Figure 53 Market Barriers
  • Figure 54 Market Opportunities
  • Figure 55 PORTER's Five Force Analysis
目次
Product Code: DIMDCL0475

Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole-Genome Sequencing, Whole-Exome Sequencing, Rna Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), by geography, is expected to grow at a significant CAGR forecast till 2030 owing to the rising application of next-generation sequencing (NGS) technology in clinical diagnosis and advancement in NGS platforms

The global Next-Generation Sequencing market was valued at USD 9.28 billion in 2023, growing at a CAGR of 18.96% during the forecast period from 2024 to 2030, to reach USD 26.30 billion by 2030. The increase in demand for Next-Generation Sequencing is primarily attributed to the rising cases of infectious diseases such as the sudden outbreak of COVID-19 and the escalating burden of cancer, worldwide. Moreover, the rising application of NGS technology in clinical diagnosis and scientific research, and advantages such as efficient turnaround results, high speed, and accuracy exhibited by the NGS technology, among others are some of the factors that would contribute to the global Next-Generation Sequencing market growth in the forthcoming years.

Next-Generation Sequencing Market Dynamics:

The market for Next-Generation Sequencing is gaining pace at present due to the surge in COVID-19 infected people across the globe. This is because the Covid virus has evolved from the time of its outbreak and PCR testing only determines the presence of the virus. Whereas, NGS technology is used in determining the novel strains of the COVID-19 virus as well as its surveillance.

According to the World Health Organization (WHO), 22 December 2022 data, approximately 275,233,892 confirmed cases of COVID-19 were reported across the globe.

In addition, the increasing burden of cancer cases worldwide is also anticipated to contribute to the Next-Generation Sequencing market. This is because of the rising significance of NGS technology-based platforms for the detection of cancer biomarkers. According to the data published by the GLOBOCAN directory in the year 2020, approximately 19,292,789 new cases of cancer were detected, globally in the same year.

Furthermore, NGS technology-based product approvals for the detection of various disorders such as infectious diseases, genetic disorders, among others are expected to contribute to the market for Nex Generation Sequencing during the forecasted period. For instance, on September 08, 2020, the US FDA granted pre-market approval to the Oncomine Dx Target test, developed by Thermo Fisher Scientific, as a companion diagnostic (CDx) to identify RET fusion-positive, metastatic non-small cell lung cancer (NSCLC) patients who are candidates for GAVRETO(TM) (pralsetinib), a targeted therapy developed by Blueprint Medicines. It is the first targeted next-generation sequencing (NGS)-based CDx for biomarkers associated with three FDA-approved NSCLC therapies.

However, certain factors such as short read lengths in NGS technology and the high cost of the instruments & services are likely to impede the Next-Generation Sequencing market growth.

The unprecedented COVID-19 pandemic has had a positive effect on the Next-Generation Sequencing market. This is because NGS technology is a cost-effective molecular test for the diagnosis of COVID19, which uses a single-step RNA extraction and presents high scalability and accuracy when compared to the gold-standard RT-qPCR. Furthermore, the rise in emergency use authorizations (EUAs) for Next-Generation Sequencing tests for SARS-CoV-2 has also led to market growth during the pandemic crisis. For instance, on June 10, 2020, Illumina, Inc. received an Emergency Use Authorization (EUA) for the Illumina COVIDSeq(TM) Test, a high-throughput, next-generation sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2 by the US FDA. In addition, the inclusion of Next-generation sequencing (NGS) technology as a clinical diagnostic test, particularly with the COVID-19 pandemic by various laboratories has also bolstered the market during the pandemic. For instance, in August 2020, Helix Laboratory obtained the FDA approval for its COVID-19 NGS test, an amplicon-based next-generation sequencing (NGS) test developed for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens for COVID-19 suspected individuals.

Next-Generation Sequencing Market Segment Analysis:

Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Next-Generation Sequencing sequencing type segment, the whole genome sequencing (WGS) type is anticipated to hold a significant market share during the forecasted period. This is because whole-genome sequencing provides the most comprehensive data related to any organism in a short duration of time. Moreover, WGS is extensively used to develop precision medicines and personalized treatment.

For instance, on December 03, 2020, Weill Cornell Medicine, New York-Presbyterian Hospital, and Illumina, Inc. entered into a collaboration to sequence the complete human genomes of thousands of consenting patients seeking to advance the scope of precision medicine.

In addition, shifting the focus of market players towards the development of NGS-based whole genome sequencing panels for the detection of causative agents of various infections such as COVID-19 would also contribute to the segmental growth of the Next-generation Sequencing market in the upcoming years. For instance, in March 2020, the Paragon Genomics team quickly developed and launched an amplicon-based NGS panel: CleanPlex® SARS-CoV-2 Panel for sequencing the whole genome of SARS-CoV-2 (the virus responsible for COVID-19) on both Illumina and MGI Tech Sequencing platforms. The panels are designed to obtain complete viral genomes even from samples with very low SARS-CoV-2 viral content.

Thus, the aforementioned factors are projected to propel the market for next-generation based whole genome sequencing type during the forecasted period.

North America is expected to dominate the overall Next-Generation Sequencing Market:

Among all the regions, North America is expected to occupy a major share in the overall Next-Generation Sequencing market during the forecasted period. This domination is owing to the rising cases of infectious disease in the region. Furthermore, the spike in the new cancer cases, the presence of key market players and leading national clinical laboratories, and favorable reimbursement policies for the NGS technology, among others are expected to fuel the overall Next-Generation Sequencing market in the region.

For instance, on January 27, 2020, the Centers for Medicare & Medicaid Services (CMS), announced to cover FDA approved or cleared laboratory diagnostic tests using Next Generation Sequencing (NGS) for patients with germline (inherited) ovarian or breast cancer.

Moreover, a rise in research and development activities to develop advanced NGS-based instruments would contribute to the regional market. For instance, in the year 2020, DNA Script and its Molecular Encoding Consortium partners were awarded a USD 23 million multi-phase contract from the Intelligence Advanced Research Projects Activity's (IARPA) Molecular Information Storage (MIST) program. The consortium will explore the possibility of integrating a novel enzymatic DNA synthesis technology and next-generation sequencing into a single instrument throughout the program.

In addition, the rise in cancer cases in the country would also lead to an increased demand for NGS sequencing technology to provide a molecular rationale for appropriate targeted therapy. For instance, according to the data published by the GLOBOCAN directory in the year 2020, approximately, 2,281,658 new cases of cancer were reported in the US in the same year.

Additionally, strategic business activities in the region to use NGS technology to enhance the diagnostic capabilities will also contribute to the NGS market in the country during the forthcoming years. For instance, on August 12, 2020, GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company agreed with Pediatrix Medical Group to offer state-of-the-art, next-generation genomic sequencing to contribute to the clinical diagnosis in neonatal intensive care units ("NICUs") staffed by Pediatrix's affiliated neonatologists.

Hence, all the above-mentioned factors are projected to fuel the Next-Generation Sequencing market in the country.

Further, the Asia Pacific region has the future potential for the Next-Generation Sequencing market. This is predominantly due to the burgeoning cases of various infectious diseases, and the growing cancer burden in the region. Moreover, the presence of regional companies focused on developing and manufacturing advanced NGS-based systems would propel the market during the forecasted period. For instance, in 2019, Longas Technologies Pty Ltd launched Morphoseq(TM), a disruptive technology designed to improve the performance of industry-standard NGS platforms by increasing effective read lengths, with benefits in accuracy and cost-efficiency. Also, the presence of several NGS service providers in the region would contribute to the market. For instance, MedGenome offers Next Generation Sequencing services to more than 8000 clinicians with over 1600 hospitals across South Asia and India.

Moreover, rising cases of Covid-19 in the region will escalate the demand for Next-Generation Sequencing. For instance, about 34,765,976 confirmed COVID-19 cases, and 7,495 new cases were reported in India till December 23, 2022, as per the WHO report. Also, improving healthcare infrastructure, and government initiatives in raising awareness regarding molecular diagnosis will contribute to the Next-Generation Sequencing market growth in these regions.

Next-Generation Sequencing Market Key Players:

Some of the key market players operating in the Next-Generation Sequencing market include Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation., NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics., HTG Molecular Diagnostics, Inc., and others.

Recent Developmental Activities in the Next-Generation Sequencing Market:

In December 2022, Roche launched the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine.

In May 2022, Illumina, Inc. and Next-Generation Genomics Co., Ltd. launched VeriSeq(TM) NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT).

In February 2022, INOVIO and QIAGEN expanded collaboration to develop next-generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia.

Key Takeaways from the Next-Generation Sequencing Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Next-Generation Sequencing market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the Global Next-Generation Sequencing Market.

Various opportunities available for the other competitor in the Next-Generation Sequencing Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Next-Generation Sequencing market growth in the coming future?

Target Audience who can be benefited from the Next-Generation Sequencing Market Report Study

Next-Generation Sequencing providers

Research organizations and consulting companies

Next-Generation Sequencing-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Next-Generation Sequencing

Various End-users who want to know more about the Next-Generation Sequencing Market and the latest technological developments in the Next-Generation Sequencing market.

Frequently Asked Questions for the Next-Generation Sequencing Market:

1. What is Next-Generation Sequencing?

Next-Generation Sequencing is a massively parallel technology for determining the RNA or DNA sequence to provide information regarding genetic variation associated with diseases or other biological phenomena. The technology offers scalability, high throughput, and speed thereby allowing labs to perform a wide variety of applications.

2. What is the market for Global Next-Generation Sequencing?

The global Next-Generation Sequencing market was valued at USD 9.28 billion in 2023, growing at a CAGR of 18.96% during the forecast period from 2024 to 2030, to reach USD 26.30 billion by 2030.

3. What are the drivers for the Global Next-Generation Sequencing?

The major factors driving the demand for Next-Generation Sequencing are the rising cases of infectious diseases such as the COVID-19 pandemic, and others. In addition, technological advancement, increasing incidence of cancer across the globe, and rapid product approvals in the Next-Generation Sequencing product arena are expected to augment the global Next-Generation Sequencing market.

4. What are the key players operating in Global Next-Generation Sequencing?

Some of the key market players operating in the Next-Generation Sequencing market include Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation., NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics., HTG Molecular Diagnostics, Inc., and others.

5. Which region has the highest share in the Next-Generation Sequencing market?

Among all the regions, North America is expected to occupy a major share in the overall Next-Generation Sequencing market during the forecasted period, 2024-2030. This domination is owing to the rising cases of infectious disease in the region. Furthermore, the spike in the new cancer cases, the presence of key market players and leading national clinical laboratories, and favorable reimbursement policies for the NGS technology, among others are expected to fuel the overall Next-Generation Sequencing market in the region.

Table of Contents

1.Next-Generation Sequencing Market Report Introduction

2.Next-Generation Sequencing Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Next-Generation Sequencing Market Key factors analysis

  • 4.1 Next-Generation Sequencing Market Drivers
    • 4.1.1 The rising burden of cancer worldwide
    • 4.1.2 Growing incidence of infectious diseases such as COVID-19 across the globe
    • 4.1.3 Rapid approval of Next-Generation Sequencing products
    • 4.1.4 Technological advancement in the manufacturing of Next-Generation Sequencing products
  • 4.2 Next-Generation Sequencing Market Restraints and Challenges
    • 4.2.1 High cost associated with Next-Generation Sequencing instruments and services
    • 4.2.2 Short Read Lengths in most of the NGS based platform
  • 4.3 Next-Generation Sequencing Market Opportunities
    • 4.3.1 Low and middle-income nations have tremendous opportunities for the Next-Generation Sequencing market
    • 4.3.2 Strategic business activities by the global as well as regional manufacturers will provide opportunities in the Next-Generation Sequencing market

5. Next-Generation Sequencing Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Next-Generation Sequencing Market

7. Next-Generation Sequencing Market layout

  • 7.1 By Product Type
    • 7.1.1 Instruments
    • 7.1.2 Reagents & Consumables
    • 7.1.3 Services
  • 7.2 By Sequencing Type
    • 7.2.1 Whole Genome Sequencing
    • 7.2.2 Whole Exome Sequencing
    • 7.2.3 RNA Sequencing
    • 7.2.4 Targeted Sequencing
    • 7.2.5 De-Novo Sequencing
    • 7.2.6 Others
  • 7.3 By Application
    • 7.3.1 Diagnostic
    • 7.3.2 Drug Discovery
    • 7.3.3 Agriculture & Animal Research
    • 7.3.4 Others
  • 7.4 By End-user
    • 7.4.1 Pharmaceutical & Biotechnology Companies
    • 7.4.2 Hospitals & Clinics
    • 7.4.3 Academic & Research Institute
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 North America Next-Generation Sequencing Market, by Product Type
      • 7.5.1.2 North America Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.1.3 North America Next-Generation Sequencing Market, by Application
      • 7.5.1.4 North America Next-Generation Sequencing Market, by End User
      • 7.5.1.5 North America Next-Generation Sequencing Market, by Country
      • 7.5.1.5.1 United States
      • 7.5.1.5.2 Canada
      • 7.5.1.5.3 Mexico
    • 7.5.2 Europe
      • 7.5.2.1 Europe Next-Generation Sequencing Market, by Product Type
      • 7.5.2.2 Europe Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.2.3 Europe Next-Generation Sequencing Market, by Application
      • 7.5.2.4 Europe Next-Generation Sequencing Market, by End User
      • 7.5.2.5 Europe Next-Generation Sequencing Market, by Country
      • 7.5.2.5.1 France
      • 7.5.2.5.2 Germany
      • 7.5.2.5.3 United Kingdom
      • 7.5.2.5.4 Italy
      • 7.5.2.5.5 Spain
      • 7.5.2.5.6 Russia
      • 7.5.2.5.7 Rest of Europe
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 Asia-Pacific Next-Generation Sequencing Market, by Product Type
      • 7.5.3.2 Asia-Pacific Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.3.3 Asia-Pacific Next-Generation Sequencing Market, by Application
      • 7.5.3.4 Asia-Pacific Next-Generation Sequencing Market, by End User
      • 7.5.3.5 Asia-Pacific Next-Generation Sequencing Market, by Country
      • 7.5.3.5.1 China
      • 7.5.3.5.2 Japan
      • 7.5.3.5.3 India
      • 7.5.3.5.4 Australia
      • 7.5.3.5.5 South Korea
      • 7.5.3.5.6 Rest of Asia Pacific
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 RoW Next-Generation Sequencing Market, by Product Type
      • 7.5.4.2 RoW Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.4.3 RoW Next-Generation Sequencing Market, by Application
      • 7.5.4.4 RoW Next-Generation Sequencing Market, by End User
      • 7.5.4.5 RoW Next-Generation Sequencing Market, by Region
      • 7.5.4.5.1 Middle East
      • 7.5.4.5.2 Africa
      • 7.5.4.5.3 South America

8. Next-Generation Sequencing Global Company Share Analysis - Key 3-5 Companies

9. Next-Generation Sequencing Company and Product Profiles

  • 9.1 F. Hoffmann-La Roche Ltd
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Agilent Technologies, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 Illumina Inc
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Bio-Rad Laboratories, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 QIAGEN
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Thermo Fisher Scientific Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 PerkinElmer Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 MedGenome
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 BGI
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Pacific Biosciences
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 GENEWIZ
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 Oxford Nanopore Technologies plc.
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Psomagen, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 10x Genomics
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 Takara Bio Inc.
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 Zymo Research Corporation.
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 NuGEN Technologies, Inc. (Tecan Trading AG)
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 Vela Diagnostics
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 CD Genomics.
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 HTG Molecular Diagnostics, Inc.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us